Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to ...

ImmunityBio (IBRX) stock gains as its CAR-NK cell therapy shows promise in an early stage trial, with lymphoma patients ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

Cambridge, Massachusetts Wednesday, August 13, 2025, 15:00 Hrs [IST] ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Ready to get scared? Edmonton’s iconic Deadmonton Haunted House has revealed its 2025 themes — and they’ll send chills down ...

How to get rich? The single best way is to live a long time, ideally working much of that time while amassing savings that ...

Biotech veteran Dr. Amit Rakhit shares his strategy for navigating global regulatory systems by embracing "strategic ...